Novel bioactive peptides to revolutionize anti-inflammatory steroid-sparing strategies.
Immunomodulatory peptides are a novel therapeutic class with the potential to deliver differentiated outcomes in autoimmune and inflammatory diseases including dermatology, ophtalmology and respiratory care, as standalone drugs or as part of steroid-sparing therapeutic approaches.
EVO Peptides
EVORA Biosciences develops EVO peptides. Novel, patent-protected peptides which exhibit strong anti-inflammatory potency alongside a very favorable profile for development as an immunomodulatory drug.
Selective anti-inflammatory effect
Stable
Non-toxic
Amenable to multiple formulation options
Management
Hadrien Lanvin, MSc CEO
Anna Kostrzak, PhD Head of R&D
Directors
Hadrien Lanvin, MSc CEO EVORA
Bruno Toque, PhD Ex-Founder, CEO Exonhit Therapeutics